Matthew Zirwas, M.D.

An expert discusses the existing gaps in atopic dermatitis (AD) management, promising areas of research to address unmet needs, and key takeaways from the discussion for the managed care audience regarding AD management.

An expert discusses key considerations dermatologists should keep in mind when integrating newer therapies into their clinical practice, including implementing protocols for patient monitoring and promoting treatment adherence.

An expert discusses the advancements in systemic and targeted therapies that have had the most significant impact on atopic dermatitis (AD) treatment in recent years as well as the cost-effectiveness and real-world outcomes of biologics and Janus kinase (JAK) inhibitors compared with traditional systemic therapies for AD

An expert discusses the most common barriers clinicians face when prescribing topical therapies for atopic dermatitis (AD) and their impact on patient adherence as well as strategies dermatologists can employ to navigate insurance coverage, prior authorization and step therapy to ensure patients receive appropriate care.

An expert discusses how to approach shared decision-making with patients and caregivers when selecting a treatment plan for atopic dermatitis (AD).

An expert discusses the currently available topical treatments for atopic dermatitis (AD) and their role in disease management.

An expert discusses the burden of physical symptoms and the financial impact, including indirect costs, of atopic dermatitis (AD) on patients and their families.

An expert discusses how the clinical presentations of atopic dermatitis (AD) vary across different patient populations and the challenges these variations pose in diagnosis.